Compare CBFV & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBFV | NYXH |
|---|---|---|
| Founded | 1901 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.7M | 161.9M |
| IPO Year | 2014 | 2021 |
| Metric | CBFV | NYXH |
|---|---|---|
| Price | $36.27 | $1.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $38.00 | $9.33 |
| AVG Volume (30 Days) | 6.8K | ★ 217.1K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $43,557,000.00 | N/A |
| Revenue This Year | $48.93 | $213.98 |
| Revenue Next Year | $7.97 | $126.25 |
| P/E Ratio | $49.69 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.40 | $1.26 |
| 52 Week High | $38.86 | $8.59 |
| Indicator | CBFV | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 35.62 |
| Support Level | $34.06 | $1.26 |
| Resistance Level | $36.44 | $1.70 |
| Average True Range (ATR) | 0.68 | 0.10 |
| MACD | -0.22 | 0.03 |
| Stochastic Oscillator | 17.25 | 10.98 |
CB Financial Services Incis a bank holding company headquartered in Carmichaels, Pennsylvania. The company had one reportable segment, community banking services. The Bank also has a loan production office in Allegheny County, a loan production office and a corporate center in Washington County, and an operations center in Greene County, Pennsylvania. The Bank is a community-oriented institution offering residential and commercial real estate loans, commercial and industrial loans, and consumer loans, as well as a variety of deposit products for individuals and businesses in its market area.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.